The Imperative for Diversity and Inclusion in Clinical Trials and Health Research Participation
被引:45
作者:
Bibbins-Domingo, Kirsten
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94158 USAUniv Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94158 USA
Bibbins-Domingo, Kirsten
[1
]
Heiman, Alex
论文数: 0引用数: 0
h-index: 0
机构:
Natl Acad Sci Engn & Med, Washington, DC USAUniv Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94158 USA
Heiman, Alex
[2
]
Dzau, Victor J.
论文数: 0引用数: 0
h-index: 0
机构:
Natl Acad Med, Washington, DC USAUniv Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94158 USA
Dzau, Victor J.
[3
]
机构:
[1] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94158 USA
[2] Natl Acad Sci Engn & Med, Washington, DC USA
[3] Natl Acad Med, Washington, DC USA
来源:
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
|
2022年
/
327卷
/
23期
关键词:
D O I:
10.1001/jama.2022.9083
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
This Viewpoint summarizes a report from the National Academies of Sciences, Engineering, and Medicine that details the suboptimal inclusion of women and underrepresented racial and ethnic groups in US research studies and provides approaches to better elucidate barriers, facilitators, and best practices in this endeavor.
引用
收藏
页码:2283 / 2284
页数:2
相关论文
共 1 条
[1]
NASEM, 2022, Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups